| Omega-3 EPA (dominant) | EPA-dominant omega-3 is the most evidence-supported nutritional intervention in schizophrenia. EPA reduces neuroinflammatory prostaglandins (PGE2, thromboxane A2), restores neuronal phospholipid composition, improves dopamine and serotonin receptor membrane function, increases BDNF, and specifically reduces PANSS positive symptom subscores. The Vienna omega-3 trial (Amminger et al., JAMA Psychiatry 2015) demonstrated that 7-year follow-up after 12-week omega-3 supplementation in ultra-high-risk youth showed sustained protection against psychosis onset (28% conversion rate in placebo vs. 9.8% in omega-3 group), representing the most significant preventive intervention ever demonstrated in psychiatry. | 3–4g EPA/day (use EPA-dominant formula, EPA:DHA ≥ 2:1) | With the largest meal of the day — fat dramatically increases absorption | Check Omega-3 Index before and after 3 months of supplementation — target above 8%. Use triglyceride-form fish oil (not ethyl ester) for superior bioavailability. Refrigerate after opening. Nordic Naturals ProEPA, Carlson Elite EPA, or pharmaceutical-grade EPA products are preferred. Do not use DHA-dominant formulas — EPA is the therapeutically relevant fraction for psychosis. |
| N-Acetyl Cysteine (NAC) | NAC is the rate-limiting precursor to glutathione — the primary antioxidant in the brain. Glutathione is severely depleted in schizophrenic brains (cortical glutathione measured by 1H-MRS is reduced by 52% in schizophrenia). NAC replenishes intracellular cysteine, restoring glutathione synthesis. This reduces oxidative stress, neuroinflammation, and glutamate dysregulation (via the cystine-glutamate antiporter, which modulates synaptic glutamate release). Berk et al. (2008) demonstrated significant PANSS total and negative symptom reduction with 2g/day NAC. Farokhnia et al. (2013) specifically showed improvements in auditory hallucination severity, processing speed, and working memory. | 1,800–2,000mg/day in 2 divided doses (900–1,000mg twice daily) | Away from meals for best absorption; morning and evening doses | Start at 600mg once daily for the first week, increasing by 600mg each week to minimize initial GI adaptation (mild nausea, loose stools). Effects build over 8–12 weeks — do not discontinue early if no immediate response. Take with Vitamin C 500mg to maintain NAC in the reduced (active) state. Pairs synergistically with omega-3 for comprehensive neuroinflammation and oxidative stress management. |
| Glycine | Glycine is the obligate co-agonist at the NMDA receptor glycine-B binding site — essential for NMDA receptor activation. NMDA receptor hypofunction (due to reduced glycine and D-serine at this site) is the glutamate hypothesis mechanism underlying schizophrenia's negative and cognitive symptoms. Supplemental glycine directly increases synaptic glycine concentration, partially restoring NMDA function in prefrontal cortical circuits. Heresco-Levy et al. (1999) RCT demonstrated 30–40% reduction in PANSS negative and cognitive subscores with glycine added to antipsychotics. Subsequent trials confirmed these findings. High doses required due to glycine transporter competition. | 30–60g/day in 3–4 divided doses (start at 4–8g/day, increase weekly) | With meals to improve tolerance; divide doses throughout the day to maintain consistent synaptic glycine levels | The very high doses required (30–60g) are the primary limitation — start at 4g/day and increase by 4–8g/week as tolerated. Mix in water or juice; glycine has a naturally sweet taste. Sarcosine (see below) achieves similar NMDA enhancement at much lower doses (2g) and may be preferable. Do NOT combine glycine or sarcosine with clozapine (the combination may worsen symptoms via complex glycine transporter interactions — specific contraindication documented in the literature). |
| Sarcosine (N-methylglycine) | Sarcosine is an endogenous amino acid derivative and glycine transporter-1 (GlyT-1) inhibitor — it prevents the reuptake of synaptic glycine, increasing NMDA co-agonist concentration at the glycine-B site without requiring the very high glycine supplementation doses. Multiple Taiwanese RCTs by Hsien-Yuan Lane and colleagues (2005, 2006, 2010) demonstrated significant improvement in all three PANSS symptom domains with sarcosine 2g/day added to various antipsychotics. A 2013 meta-analysis confirmed positive, negative, and cognitive symptom improvements superior to glycine in head-to-head comparisons. Sarcosine is the most practical NMDA modulator for clinical use. | 2g/day (1g twice daily) | With meals; morning and evening | Much better tolerated than high-dose glycine. Available online as pure sarcosine powder. Do NOT combine with clozapine (same contraindication as glycine). May be used instead of, or alongside, glycine — but not simultaneously with clozapine. Monitor for any changes in psychiatric symptoms when introducing; start at 1g/day and increase to 2g at 1 week if tolerated. Report to psychiatrist before initiating. |
| Methylfolate + Methylcobalamin (B12) | Elevated homocysteine (found in 30–50% of schizophrenia patients) directly impairs NMDA receptor function by competing with the glycine-B binding site, reduces BDNF, causes cerebrovascular microdamage, and disrupts monoamine synthesis. Homocysteine above 12 µmol/L is independently associated with greater cognitive impairment and negative symptom severity in schizophrenia. Active methylfolate (5-MTHF) bypasses MTHFR polymorphisms to directly lower homocysteine and support dopamine/serotonin synthesis. A Gothenburg double-blind RCT showed folic acid supplementation reduced PANSS scores and improved social functioning specifically in schizophrenia patients with high homocysteine. | Methylfolate: 1–15mg/day (based on MTHFR genotype and homocysteine levels); Methylcobalamin B12: 1,000–5,000mcg/day | Morning with breakfast | Test homocysteine and MTHFR status before dosing — target homocysteine below 8 µmol/L. If starting methylfolate causes increased anxiety or agitation ("overmethylation"), reduce dose by 50% and increase slowly. High-dose methylcobalamin may be beneficial even without B12 deficiency due to its direct neuroprotective and myelin-repair effects. Recheck homocysteine after 3 months of supplementation. |
| Vitamin D3 | Vitamin D receptors are expressed throughout the limbic system and prefrontal cortex — the primary circuits disrupted in schizophrenia. Vitamin D directly regulates: tyrosine hydroxylase (dopamine synthesis), tryptophan hydroxylase (serotonin synthesis), glutathione synthesis, BDNF expression, and anti-inflammatory cytokine production. A meta-analysis of 19 studies confirms significantly lower Vitamin D levels in schizophrenia versus healthy controls — and lower D levels correlate with higher PANSS severity. Prenatal Vitamin D deficiency is a well-established environmental risk factor for schizophrenia — maternal D deficiency doubles offspring risk. A 12-week RCT showed adjunctive Vitamin D significantly improved PANSS total and general psychopathology scores. | 5,000 IU/day for 3 months, then 2,000–3,000 IU maintenance (test-guided) | With the largest fat-containing meal of the day (fat-soluble) | Test 25(OH)D before supplementing — baseline is almost universally low in schizophrenia. Target 50–80 ng/mL. Re-test at 3 months. Higher body weight (antipsychotic-induced weight gain) requires higher doses. Combine with K2 MK-7 (100mcg/day) to ensure calcium is directed to bone rather than soft tissue. Magnesium is required for Vitamin D conversion to its active form — deficiency of magnesium impairs Vitamin D effectiveness. |
| Zinc (Picolinate) | Zinc is an allosteric modulator of NMDA receptors (reduces pathological overactivation while allowing physiological function), a cofactor for dopamine β-hydroxylase and BDNF synthesis, and an essential component of over 300 enzymes involved in neurotransmitter and antioxidant metabolism. Zinc deficiency is prevalent in schizophrenia — and critically, an elevated copper-to-zinc ratio (above 1.2) is specifically associated with psychotic symptom severity. High copper is independently pro-inflammatory and may drive both positive and inflammatory symptom burden. Zinc supplementation both corrects zinc deficiency and normalizes the Cu:Zn ratio. A placebo-controlled trial showed zinc augmentation improved PANSS scores in schizophrenia patients with zinc deficiency. | 30–50mg elemental zinc (as picolinate), titrated based on Cu:Zn ratio | With food — prevents nausea; evening preferred | Measure serum zinc AND serum copper together — calculate the Cu:Zn ratio (target below 1.0). High-dose zinc over 40mg/day depletes copper further — monitor with repeat testing at 3 months. Zinc picolinate is the best-absorbed form. Do not take within 2 hours of thyroid medication. If the Cu:Zn ratio is already normal, use lower doses (25mg/day). Pairs synergistically with NAC (both support glutathione) and Vitamin D. |
| Vitamin C (Ascorbic Acid) | The brain concentrates Vitamin C at 10x plasma levels — reflecting its critical role in catecholamine synthesis (dopamine-β-hydroxylase is Vitamin C-dependent), collagen integrity of blood-brain barrier, and as the primary water-phase antioxidant protecting against oxidative neuroinflammation. Antipsychotic medications generate significant reactive oxygen species — dramatically increasing Vitamin C requirements. Controlled trials in schizophrenia show high-dose Vitamin C reduces lipid peroxidation markers and improves scores on measures of negative symptoms and cognition. Hoffer's orthomolecular protocol used 3,000–10,000mg/day vitamin C as a foundational intervention. | 2,000–4,000mg/day in divided doses (500–1,000mg with each meal) | With meals — dividing doses throughout the day maintains stable plasma levels (half-life: 4–6 hours) | Bowel tolerance varies — reduce dose if diarrhea occurs (osmotic diarrhea at high doses is the dose-limiting effect). Use buffered Vitamin C (calcium or magnesium ascorbate) or liposomal Vitamin C for better GI tolerance at higher doses. Liposomal Vitamin C achieves significantly higher plasma levels than standard oral ascorbic acid. Take alongside NAC — they work synergistically to maintain antioxidant activity in both water-phase (Vitamin C) and lipid-phase (glutathione / omega-3). |
| Magnesium Glycinate | Magnesium is an NMDA receptor channel blocker at physiological concentrations — it sits within the NMDA channel and prevents excessive calcium influx, protecting against excitotoxicity. Magnesium deficiency removes this neuroprotective blockade, enabling pathological NMDA activation. Magnesium is also required for the activation of Vitamin D (magnesium-dependent enzymes convert D to its active form), for ATP synthesis (magnesium-ATP is the biologically active energy currency), and for the regulation of the HPA stress axis. Antipsychotic medications further deplete magnesium. Intracellular magnesium deficiency is common in schizophrenia and directly worsens NMDA dysfunction. | 400–600mg elemental magnesium (as glycinate) per day | 300mg with dinner; additional 200mg at bedtime for sleep support | Glycinate is the best-tolerated and highest-bioavailability form — avoids the laxative effect of oxide and citrate at these doses. RBC magnesium (not serum) accurately reflects intracellular status — test before supplementing. Magnesium deficiency impairs Vitamin D conversion — ensure both are supplemented together. The glycinate form also provides additional glycine (as the chelate) — providing a small but meaningful additional NMDA co-agonist effect. |
